This could pave the way for the usage of these alleles in patient stratification (carriers and noncarriers)—as already happens with various HLA-DRB1 alleles and especially with the HLA-DRB1*15 allele [4,42]—for many MS characteristics and therapy responses in different DMTs in Caucasian populations [4,42]. Here, HLA-DRB1 is linked to myeloid sarcoma.